These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 3552281)

  • 1. N-methyl antitumour agents. A distinct class of anticancer drugs?
    Newell D; Gescher A; Harland S; Ross D; Rutty C
    Cancer Chemother Pharmacol; 1987; 19(2):91-102. PubMed ID: 3552281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbinolamines and related structures--potential alkylating metabolites of clinically active anticancer drugs.
    Soloway AH; Brumbaugh RJ; Witiak DT
    J Theor Biol; 1983 Jun; 102(3):361-73. PubMed ID: 6225911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triazene compounds: mechanism of action and related DNA repair systems.
    Marchesi F; Turriziani M; Tortorelli G; Avvisati G; Torino F; De Vecchis L
    Pharmacol Res; 2007 Oct; 56(4):275-87. PubMed ID: 17897837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chemosensitivity of a new experimental model--the M5076 reticulum cell sarcoma.
    Langdon SP; Gescher A; Hickman JA; Stevens MF
    Eur J Cancer Clin Oncol; 1984 May; 20(5):699-705. PubMed ID: 6428895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinogenicity of cytostatic triazenes.
    Kolar GF
    IARC Sci Publ; 1986; (78):111-26. PubMed ID: 3583385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-methylformamide: antitumour activity and metabolism in mice.
    Gescher A; Gibson NW; Hickman JA; Langdon SP; Ross D; Atassi G
    Br J Cancer; 1982 Jun; 45(6):843-50. PubMed ID: 7201320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism.
    Ross D; Langdon SP; Gescher A; Stevens MF
    Biochem Pharmacol; 1984 Apr; 33(7):1131-6. PubMed ID: 6424683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitrosoureas: a review of experimental antitumor activity.
    Schabel FM
    Cancer Treat Rep; 1976 Jun; 60(6):665-98. PubMed ID: 782694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triazene metabolism. III. In vitro cytotoxicity towards M21 cells and in vivo antitumour activity of the proposed metabolites of the antitumour 1-aryl-3,3-dimethyltriazenes.
    Kohlsmith DJ; Vaughan K; Luner SJ
    Can J Physiol Pharmacol; 1984 Apr; 62(4):396-402. PubMed ID: 6733585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutagenic and chemotherapeutic activity in L1210 leukemia of several monofunctional alkylating agents.
    Schmid FA; Otter GM; Mehta BM
    Cancer Res; 1985 Jan; 45(1):40-4. PubMed ID: 3965147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of anticancer drugs.
    Chabner BA; Myers CE; Oliverio VT
    Semin Oncol; 1977 Jun; 4(2):165-91. PubMed ID: 69319
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer chemotherapy: implications for the anesthesiologist.
    Selvin BL
    Anesth Analg; 1981 Jun; 60(6):425-34. PubMed ID: 7015924
    [No Abstract]   [Full Text] [Related]  

  • 13. Biochemical and pharmacologic properties of nitrosoureas.
    Wang AL; Tew KD; Byrne PJ; Schein PS
    Cancer Treat Rep; 1981; 65 Suppl 3():119-24. PubMed ID: 7049367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating effect of new potential antimelanomic agents, spin-labeled triazenes and nitrosoureas on the DOPA-oxidase activity of tyrosinase.
    Gadjeva V; Zheleva A; Raikova E
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):99-108. PubMed ID: 10738906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance.
    Kyrtopoulos SA; Anderson LM; Chhabra SK; Souliotis VL; Pletsa V; Valavanis C; Georgiadis P
    Cancer Detect Prev; 1997; 21(5):391-405. PubMed ID: 9307842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinogenicity of alkylating cytostatic drugs in animals.
    Berger MR
    IARC Sci Publ; 1986; (78):161-76. PubMed ID: 3583389
    [No Abstract]   [Full Text] [Related]  

  • 17. Alkylating agent and chromatin structure determine sequence context-dependent formation of alkylpurines.
    Cloutier JF; Castonguay A; O'Connor TR; Drouin R
    J Mol Biol; 2001 Feb; 306(2):169-88. PubMed ID: 11237592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies.
    Coley HM; Brooks N; Phillips DH; Hewer A; Jenkins TC; Jarman M; Judson IR
    Biochem Pharmacol; 1995 May; 49(9):1203-12. PubMed ID: 7763301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytostatic action of two nitrosoureas derived from cysteamine.
    Bourut C; Chenu E; Godenèche D; Madelmont JC; Maral R; Mathé G; Meyniel G
    Br J Pharmacol; 1986 Nov; 89(3):539-46. PubMed ID: 3801787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,3-Dialkyl-3-acyltriazenes, a novel class of antineoplastic alkylating agents.
    Smith RH; Scudiero DA; Michejda CJ
    J Med Chem; 1990 Sep; 33(9):2579-83. PubMed ID: 2391696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.